Publications by authors named "Mark Rametta"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

6,135

Total Likes

203

Extended Reach

20,785

Social Features

9
V
Vitamin D and Multiple Sclerosis: A Comprehensive Review.
Martina B Sintzel, Mark Rametta, Anthony T Reder

Neurol Ther· June 2018

Videos about Article: user user

2 4 7 2 41

View All Article and Social Media Activity
A
A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector.
Ryan Farej, Mark Rametta, Anneliese La Rose, Apryl Quillen, Kim McLeod

Neurol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT Autoinjector: A Retrospective Cohort Study.
Oisín Butler, Simone Heeg, Katsiaryna Holl, Ann-Kathrin Frenz, Eva-Maria Wicklein, Mark Rametta

Drugs Real World Outcomes· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sentiment of Media Coverage and Reputation of the Pharmaceutical Industry.
Valentina Pampulevski, Jessica R Giaquinto, Mark Rametta, Michael Toscani, Joseph Barone

Ther Innov Regul Sci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
Donald A Barone, Barry A Singer, Lubo Merkov, Mark Rametta, Gustavo Suarez

Neurol Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Tjalf Ziemssen, Lauren Sylvester, Mark Rametta, Amy Perrin Ross

Neurol Ther· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of death among commercially insured multiple sclerosis patients in the United States.
Douglas S Goodin, Michael Corwin, David Kaufman, Howard Golub, Shoshana Reshef, Mark J Rametta

PLoS One· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis.
Anthony T Reder, Joel F Oger, Ludwig Kappos, Paul O'Connor, Mark Rametta

Mult Scler Relat Disord· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START Study.
Suhayl Dhib-Jalbut, Clyde Markowitz, Payal Patel, Francis Boateng, Mark Rametta

Int J MS Care· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Douglas S Goodin, George C Ebers, Gary Cutter, Stuart D Cook, Timothy O'Donnell, Mark Rametta

BMJ Open· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, Kouichi Ito, Payal Patel, Mark Rametta

J Neuroimmunol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis